## Way Forward:

## Post-2029 UN drugs plan of action: One-year delay & countries inputs

This Statement was initially read during the thematic discussions of the 6th intersessional meeting of the 6oth Commission on Narcotic Drugs.



## **CIVIL SOCIETY ENGAGEMENT**

In our 2016 address to the 60th Commission, we asked to "plug the CND on <u>UN webTV</u>, a broadcasting system of the UN Department of Public Information which allows for quality multilingual video diffusion as well as archival" and "to increase the effort of presence and visualization on social media."

We are satisfied to see these demands have been met. We welcome the work of successive CND chairs and the secretariat in this regard, and recall the need to continue sustaining efforts to allow substantive involvement & contributions from all civil society stakeholders, including people who use or produce drugs and other affected populations.

## WAY FORWARDS: THE VIENNA 2029 & NEW-YORK 2030 TARGETS

**Regarding the way forward**: Ahead of 2029, and in preparation for any future plan of action, more substantive discussions should be held before concluding future commitments. Enough time and comprehensive data are critical. In this regard, we urge the CND to take these steps:

- → In the spirit of the CND Resolution 58/8, compile into a series of reports all Member States' national/local strategies and plans of action on drugs. Dedicate intersessional CND meetings in the period 2024–2029 to the presentation, debate, and discussion of these real-life drug policies and local strategies. This would foster an amenable downstream approach which could only but improve the future action plan's relatability and encourages good practice sharing.
- → Harmonize the timeframe of the CND action on drugs with the 2030 Sustainability Agenda: by extending the consultation one year (2029–2023) and adopting the future plan of action in 2030, in coordination with work on the assessment of the 2030 Agenda and discussions on the post-2030 SDG framework.

The post-2029 UN drugs plan of action must directly be a synthesis of the diversity and experiences from Member States' local and national drug strategies, and stop evolving in a parallel universe to the international commitments on global action and sustainability.